How is Burna AI different from Flatiron Health?

Flatiron Health captured real-world evidence (RWE) during active oncology treatment and was acquired by Roche for $1.9 billion in 2018. Flatiron was pre-AI and single-sided: it served the data buyer (pharma RWE), not the data producer (the oncologist). Burna AI captures structured, citation-bound, attribution-scored adverse event data and is AI-native and two-sided: the same platform serves the cancer center coordinator who produces the data and the pharma sponsor who needs the data quality. The total addressable market is larger, spanning Phase 1 trial through 20 years postmarket pharmacovigilance, $15 to $20 billion+ across the drug lifecycle.